Teva Pharmaceuticals received FDA approval for the first generic glucagon-like peptide-1 (GLP-1) agonist aimed at weight management, targeting adults struggling with excess weight and adolescents over 60 kilograms. The injectable, liraglutide-based medication mimics the natural GLP-1 hormone to stimulate insulin release and suppress appetite by acting on gut-brain pathways. With a shorter half-life than other GLP-1 competitors, the daily injection offers a lower-cost alternative amid widespread market shortages. This launch could address increasing demand for GLP-1 therapies, revolutionizing treatment options for obesity management.